Background: How we got here
From 2022 through early 2025, compounding pharmacies could legally produce semaglutide and tirzepatide under a shortage-based exemption. When brand-name GLP-1 drugs (Ozempic, Wegovy, Mounjaro, Zepbound) faced critical supply constraints, the FDA's drug shortage list allowed compounders to fill the gap.
That window closed when manufacturers resolved supply chains. The FDA removed semaglutide from the shortage list in May 2025 and tirzepatide shortly after. With the shortage designation gone, the legal basis for most commercial-scale GLP-1 compounding disappeared.
Shortage-era compounding
Both 503A and 503B pharmacies could compound semaglutide and tirzepatide under shortage-list exemptions. Market expanded dramatically.
FDA removes semaglutide from shortage list
The legal basis for bulk 503B semaglutide compounding ended. FDA issued guidance requiring cessation of commercial-scale compounding.
Enforcement and litigation period
FDA sent warning letters to 503B facilities. Legal challenges from compounders delayed some enforcement. Courts largely upheld FDA authority.
Compliant pathways established
503A patient-specific compounding remains available with documented clinical need. Certain salt forms (semaglutide sodium) occupy a legal gray zone. Personalized dosing continues via compliant 503A partners.
What's currently allowed vs. prohibited
Generally still permitted
- 503A patient-specific semaglutide compounding with valid prescription and documented clinical rationale
- Tirzepatide 503A compounding in states where shortage designation was maintained
- Alternative GLP-1 receptor agonists not currently subject to FDA removal action
- Personalized dosing modifications (e.g., dose titration schedules not available in commercial form)
- Compounding for patients with documented allergies or intolerances to commercially available formulations
No longer permitted
- 503B bulk commercial-scale semaglutide compounding (shortage exemption ended)
- Office-stock semaglutide vials from 503B facilities (shortage basis removed)
- Copy-cat commercial semaglutide products from compounders (without clinical need documentation)
- Marketing compounded semaglutide as equivalent to Ozempic or Wegovy
- Sourcing from pharmacies that continued bulk production after FDA enforcement actions
⚠️ The "semaglutide sodium" gray zone
Some compounders argue that semaglutide sodium (a salt form not identical to the active ingredient in Ozempic) is not subject to the FDA's prohibition. The FDA disputes this interpretation. Clinics sourcing semaglutide sodium compounds face meaningful legal and liability risk. Our position: avoid until courts or FDA provide definitive clarity.
The compliant pathway in 2026
Patient-specific 503A compounding
This remains the most defensible path. A licensed physician writes a prescription for a specific patient, citing the clinical need for a compounded formulation (e.g., specific dosing schedule, combination therapy, documented intolerance to commercial formulation). A 503A pharmacy compounds to that specific prescription.
What documentation supports a valid 503A prescription?
Strong documentation includes: (1) patient's BMI/metabolic panel, (2) rationale for compounded dosing vs. commercial formulation, (3) titration schedule specific to that patient, (4) documented attempt to access commercial supply when feasible. This creates a defensible medical record if questioned by regulators.
Alternative GLP-1 and metabolic therapies
Several peptides with metabolic effects remain outside the current enforcement focus — including BPC-157 (for metabolic support), certain combination therapies, and other agents where shortage designations may still apply in some states. Regulations vary state by state, and this landscape continues to evolve.
Checking current shortage status
The FDA maintains a real-time drug shortage database. Before sourcing any compounded GLP-1 therapy, verify the current shortage status:
Check FDA Shortage Status
→ FDA Drug Shortages Database
→ FDA Guidance: Compounding and Drug Shortages
Shortage status for specific drugs changes — check directly, don't rely on pharmacy representations alone.
State-level variation matters
Several states had independent shortage designations for GLP-1 drugs that may differ from federal FDA status. State boards of pharmacy have their own authority over 503A compounding within state lines. A clinic in one state may have different options than a clinic in another.
States with active compounding-friendly policies (as of early 2026) include California, Texas, Florida, and several others — but this changes. Always verify with your state board and legal counsel.
What Veridian's network uses
Every pharmacy in Veridian's network has been reviewed for compliance with post-shortage FDA guidance. We do not work with pharmacies that are under FDA warning letters or that continue bulk 503B GLP-1 production in violation of current guidance. Our network focuses on:
- → 503A pharmacies with documented patient-specific protocols
- → Non-GLP-1 metabolic therapies where compounding remains clearly legal
- → Partners with clean FDA enforcement history
- → Active BAAs and PCAB/NABP accreditation where applicable
Veridian's licensed pharmacy network is continuously monitored for compliance
Our team monitors regulatory changes and removes any pharmacy that falls out of compliance. You get the benefit of our vetting without the legal research overhead.
Apply for Access →